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Abstract
During the last decade, extensive research has been
performed in the field of orthopedic medicine to develop
cell-based therapies for the restoration of injured bone
tissue. We previously demonstrated that human primary
fetal bone cells (HFBCs) associated with porous scaffolds
induced a bone formation in critical calvaria defect;
however, the environmental factors regulating their
behavior in culture have not been identified. HFBCs (human
fetal femur,12 week development) were compared to
marrow-derived human mesenchymal stem cells (HMSCs)
for their capacity to proliferate and differentiate into
osteoblasts under various culture conditions. When cultured
in standard αMEM medium, PDGF and FGF-2 increased
cell proliferation of both cell types. Investigation of the
differentiating capacity of HFBCs and HMSCs in a normal
culture medium indicated that HFBCs expressed higher
expression levels of RUNX2, OSX, and osteogenic markers
compared with HMSCs, while SOX9 was expressed at very
low levels in both cells types. However, HMSCs, but not
HFBCs enhanced osteoblastic markers in response to
osteogenic factors. Surprisingly, BMP-2 with osteogenic
factors increased cell numbers and reduced osteoblastic
differentiation in HFBCs with the opposite effect seen in
HMSCs. Associated with a higher expression of osteoblastic
markers, HFBCs produced a higher calcified extra cellular
matrix compared with HMSCs. Taken together, data
presented in this study suggest that HFBCs have
characteristics of osteoprecursor cells that are more
advanced in their osteogenesis development compared with
mesenchymal stem cells, making fetal cells an interesting
biological tool for treatment of skeletal defects and diseases.
Keywords: Proliferation, differentiation, fetal bone cells,
mesenchymal stem cells, growth factors, environmental
conditions.
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Introduction
During the last decade, extensive research has been
performed in the field of orthopedic medicine to develop
cell-based therapies for the restoration of injured bone
tissue (Ohgushi and Caplan, 1999; Bianco et al., 2001;
Rose and Oreffo, 2002; Mauney et al., 2005; Oreffo et
al., 2005; Yoshioka et al., 2007) or the treatment of
musculoskeletal disease symptoms related to osteogenesis
imperfecta (Horwitz et al., 1999; Horwitz et al., 2001;
Horwitz et al., 2002; Chamberlain et al., 2004; Le Blanc
et al., 2005). A progressive approach in the field of skeletal
tissue engineering is to combine cells with three-
dimensional porous biocompatible materials or scaffolds
with or without appropriate growth factors (Quarto et al.,
2001; Hutmacher and Sittinger 2003; Mendes et al., 2004;
Montjovent et al., 2004; Montjovent et al., 2005; Weir
and Xu, 2010).
Adult human bone marrow-derived stem cells, also
referred to as multipotent mesenchymal stromal cells or
mesenchymal stem cells (HMSCs) (Friedenstein et al.,
1976; Caplan and Bruder, 2001; Horwitz et al., 2005) can
be easily isolated, expanded (Jaiswal et al. 1997), and
induced to differentiate into bone, cartilage, fat and other
connective tissues (Owen et al., 1987; Pittenger et al.,
1999). The potency of these cells has generated
considerable biological and clinical interest for bone tissue
regeneration (Krebsbach et al., 1999). However, stromal
cell population heterogeneity in culture and the
inconsistent definition of their properties have been
identified (Phinney et al., 1999). Another source of
biological material, fetal tissue-specific cells have been
used for cell therapy (Clarkson, 2001; Rosser and Dunnett,
2003). For musculoskeletal tissues, high cellular
expression has been shown (Hohlfeld et al., 2005; De
Buys Roessingh et al., 2006; Hirt-Burri et al., 2008a).
Cell banks were developed from only one donor and their
safety was analyzed for clinical trials where these fetal
cells were shown to successfully repair skin in acute and
chronic wounds and burns in Phase I and II human trials
(Quintin et al., 2007; Applegate et al., 2009; Ramelet et
al., 2009).
Considering the increasing clinical potential of fetal
cells for tissue engineering, human fetal bone cells
(HFBCs) have been characterized in vitro. It has been
previously shown that these cells proliferated more rapidly
than adult primary osteoblasts and could produce a
mineralized bone matrix when cultured in an osteogenic
medium (Montjovent et al., 2004) or in combination with
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adequate scaffolds (Montjovent et al., 2008). Some of these
observations have also been previously reported
(Mirmalek-Sani et al., 2006). This group communicated
that these cells are multipotent when cultured in appropriate
media, a characteristic of progenitor cells. In parallel, we
demonstrated the HFBC capability to promote bone repair
in vivo when combined with porous scaffolds based on
poly(L-lactic acid) (Montjovent et al., 2008), results
confirming our clinical studies using human fetal skin cells
(Hohlfeld et al., 2005; Hirt-Burri et al., 2008b).
To date, little information is available concerning the
behavior of HFBCs in culture and of factors regulating
their growth and differentiation. Since these cells have
characteristics of progenitor cells (Mirmalek-Sani et al.,
2006), we compared their capacity to proliferate and
differentiate with those of HMSCs cultured in an
osteogenic medium.
Materials and Methods
Reagents and growth factors
Phosphate-buffered saline pH 7.4 (PBS), L-glutamine,
antibiotics and trypsin/EDTA were obtained from Gibco
(Life Technologies, Basel, Switzerland). Fetal bovine
serum (FBS), L-ascorbic acid, β-glycerophosphate,
dexamethasone, and type I collagenase were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s
modified Eagle medium (DMEM), DMEM/Ham’s F-12
medium, α-modified essential medium (αMEM), and non-
essential amino acids were purchased from Amimed
(Bioconcept, Allschwill, Switzerland).
Human recombinant bone morphogenetic protein-2
(BMP-2, 50 ng/ml) and Indian hedgehog N-terminus (Ihh,
10 ng/ml) were obtained from R&D Systems (Minnesota,
MN, USA); platelet-derived growth factor (PDGF-BB, 10
ng/ml) was purchased from Invitrogen (Carlsbad, CA,
USA); fibroblastic growth factor-acidic (FGF-1, 10 ng/
ml), fibroblastic growth factor-basic (FGF-2, 10 ng/ml),
epidermal growth factor (EGF, 10 ng/ml), and insulin-like
growth factor-1 (IGF-1, 10 ng/ml) were purchased from
Sigma-Aldrich, parathyroid hormone-like related protein
(PTHrP, 10 ng/ml) was obtained from Promokine
(Heidelberg, Germany); Wnt3a and Wnt5a (cmWnt) were
isolated from 20% conditioned medium from L-cells stably
transfected with cDNA of either Wnt3a or Wnt5a,
respectively. BMP-2 (50 ng/ml) and CGP77675 (5 µM)
were generous gifts from Wyeth Research (now Pfizer,
New York City, NY, USA) and Novartis (Basel,
Switzerland) respectively. Selective inhibitors of MAP
kinase pathways (U0126, SB202190 and SP600125) and
GO6983 were purchased from TOCRIS (Bristol, UK).
Cell sources
Human primary fetal bone cells (HFBC) were obtained
from our dedicated, consistent banks of bone cells
comprising several fetal donors (from 11 to 16 gestational
weeks of development). In this study, we analyzed two
preparations of HFBCs from human fetal femurs
(gestational development: 12 weeks, range 11 to 13; and
14 weeks, range 12 to 15), following voluntary pregnancy
interruptions. Fetal biopsies were obtained in accordance
with the Ethical Committee of the University Hospital of
Lausanne (Ethical Protocol 51/01). Unless otherwise
specified, results presented in this study are derived from
the 12-week-old fetal tissue. Similar data were obtained
with the 14-week-old fetal bone cells. For comparison,
bone marrow-derived human adult mesenchymal stem cells
(HMSCs), commercially obtained from Cambrex
BioScience (Walkersville, MD, USA), were also
investigated in this study.
Isolation of fetal osteoblasts
Fetal femurs were first placed in DMEM containing 100
IU/ml penicillin and 100 µg/ml streptomycin for transport
to specialized culture facilities. Cultures of primary HFBC
were established by rinsing the entire femoral tissue with
sterile PBS containing antibiotics. Afterwards, the entire
femur – diaphysis with the two epiphyses (length: 10-
15mm) – was mechanically dissected with a scalpel blade,
and the resulting small pieces of bones were plated into a
4 cm Petri dishes containing 2 ml of DMEM medium in a
5% CO2 humidified atmosphere, supplemented with 2mM
L-Glutamine, 10% FBS (= medium A) during 24 hours.
The following day, the volume of medium A was completed
to 10 ml for 7 days. Cell outgrowth from bone tissues (=
migrating cells) was observed within 1-5 days under
normal culture conditions. These migrating cells continued
to develop and proliferate in medium A for 9-15 days with
a twice weekly change of medium before expansion and
cell bank freezing in 50-100 vials with 2 x 106 cells in
each vial at -80°C. Vials of cells from specific passages
were then expanded for use in experiments.
Cell culture
HFBCs and HMSCs were maintained by passaging once
a week in αMEM culture medium at 37°C with a 5% CO2
humidified atmosphere supplemented with 10% FBS, 2
mM L-glutamine, 0.5% non-essential amino acids (vol/
vol), 100 IU/ml penicillin and 100 µg/ml streptomycin.
Culture medium was changed twice a week. When
reaching confluence, cells were detached using trypsin-
EDTA and seeded at 3 x 103 cells per cm2 in T75 flasks.
Both cell types were passaged up to a maximum of 5 times
and used from passage 2 to passage 6. Human osteoblast-
like MG-63 cells (American Type Culture Collection,
Manassas, VA, USA) were maintained in basal αMEM
medium containing supplements. Approaching confluence,
after 3-4 days, these cells were detached using trypsin-
EDTA and used for further studies.
For differentiation experiments, all types of cells were
exposed to osteoblastic differentiation promoting factors
such as 50 µg/ml L-ascorbic acid, 5 mM β-
glycerophosphate, 100 nM dexamethasone, with or without
50 ng/ml BMP-2.
Measurement of cell replication
To determine the influence of culture conditions on HFBCs
and HMSCs proliferation, cells were seeded at 6000 cells/
cm2 in 12-well multi-plates containing one of the three
different media (DMEM, DMEM/Ham’s F-12, or αMEM)
containing 10% FBS, 2mM L-glutamine and antibiotics
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(= proliferation media). Every third day, up to 20 days,
cells were washed with PBS, detached with type I
collagenase and trypsin-EDTA, and counted by cell
counting (Cell Coulter counter; BeckmanCoulter, Brea,
CA, USA). Growth factors, investigated here (mentioned
above), were tested on cells maintained in αMEM with
3% FBS for 48 hours. When various inhibitors of signaling
pathways were investigated for the response to BMP-2,
agents or vehicle (DMSO) were added 15 min before
incubation with BMP-2.
RNA extraction and cDNA synthesis
Cells were first seeded in 12-well multi-plates containing
αMEM culture medium until 90% confluence, and
switched to αMEM osteogenic medium for 10 days. Total
RNA was extracted from cell layers using the Trizol reagent
as described in the manufacturer’s instructions (Invitrogen)
and subjected to DNAse I (DNA-free kit, Ambion,
Cambridge, UK). Extracted RNA was then reverse
transcribed using the multiscribe reverse transcriptase
synthesis system (Roche Molecular Systems, Branchburg,
NJ, USA).
Real-time quantitative PCR
After RNA extraction and cDNA synthesis, quantitative
RT-PCR reactions were performed with the SYBR Green
PCR Master Mix method (Applied Biosystems,
Warrington, UK). Amplifications were monitored with the
Applied Biosystems Step One PlusTM real time PCR System
for primers described in Table 1. Gene expression values
were calculated using the comparative threshold cycle
(2-∆∆CT) method, normalized to the housekeeping gene
GAPDH expression, and compared with the ∆CT calibrator
value from the untreated group. Results of three combined
measurements have been presented (each sample in
duplicates) and expressed as mean ± SEM.
Alkaline phosphatase activity assay
Alkaline phosphatase activity (ALP) was determined by
p-nitrophenyl phosphate reaction. Briefly, cells were
seeded at 6000 cells/cm2 in 12-well multi-plates and
incubated for 24 hours at 37°C in a humidified, 5% CO2
atmosphere in proliferation medium. At 90% confluence,
cells were exposed to the osteogenic medium with or
without 50 ng/ml BMP-2 for one week. The medium was
renewed after three days. Cells were detached from the
plate with a cell scraper, harvested in 1ml of distilled water
and disrupted by sonication. The homogenate was
centrifuged at 5000 rpm at 4°C for 5 minutes, and ALP
was determined in the supernatant using 100 mM p-
nitrophenyl phosphate at 37°C. The product was measured
at 405 nm, and ALP activity was normalized to the total
protein content determined by a Micro BCA protein assay
(Socochim, Pierce, Lausanne, Switzerland).
Histological analysis
Paraffin wax sections of 10 µm from a human fetal femur
(12-week-old development) were first deparaffinized and
hydrated with water. Sections were stained in Mayer’s
hematoxylin solution, washed and counterstained in
Resorsin to visualize the cell distribution and morphology,
and different tissue structures.
In vitro extracellular matrix mineralization
Cells were seeded at 6000 cells/cm2 in 35 mm Petri dishes
in basal αMEM medium containing 10% FBS with or
without BMP-2 (50 ng/ml), antibiotics and 2mM glutamine
for 4 days. Mineralization was induced by culturing
confluent monolayer cells in the osteogenic medium for
21 days. The medium was changed twice a week. In vitro
mineralized nodule formation was evaluated using the
Alizarin Red Staining (ARS) method (Gregory et al.,
2004). ARS was prepared in distilled water at a
Gene Accession number Primer sequence: sense/antisense Amplicon 
GAPDH NM_002046 5’ AACTTTGGTATCGTGGAAGG 3’ 
5’ CAGTAGAGGCAGGGATGATGT 3’ 
114 bp 
ALP NM_000478 5’ GCCTACCAGCTCATGCATAAC 3’ 
5’ GAAGTGGGAGTGCTTGTATCT 3’ 
193 bp 
COL1A1 NM_000088 5’ ACTGGTGAGACCTGCGTGTA 3’ 
5’ CCAGTCTGCTGGTCCATGTA 3’ 
263 bp 
OCN NM_199173 5’ CTCACACTCCTCGCCCTATT 3’ 
5’ GCTCCCAGCCATTGATACAG 3’ 
167 bp 
OSX NM_152860 5’ GGCACAAAGAAGCCGTACTC 3’ 
5’ TGGGAAAAGGGAGGGTAATC 3’ 
164 bp 
RUNX2 NM_001024630 5’ TTACTGTCATGGCGGGTAAC 3’ 
5’ GGTTCCCGAGGTCCATCTA 3’ 
220 bp 
COL2A1 NM_001844 5’ TGGCTTCCATTTCAGCTATG 3’ 
5’ CATCCTTCAGGGCAGTGTAC 3’ 
245 bp 
SOX9 NM_000346 5’ ACCCGCTCACAGTACGACTA 3’ 
5’ AGGTCGAGTGAGCTGTGTGTA 3’ 
223 bp 
CD44 NM_000610 5’ GCAAACAACACAGGGGTGTA 3’ 
5’ AGTAGGGTTGCTGGGGTAGA 3’ 
228 bp 
CD90 NM_006288 5’ AGTGCTGCATGCGATTATCT 3’ 
5’ GTACCCCACCATCCCACTAC 3’ 
218 bp 
Table 1. Primer sequences of human genes used for quantitative PCR analysis
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concentration of 20 mM pH 4.2 and samples were read at
595 nm in 96-well plates using a Wallac 1420 VICTOR2
multilabel plate reader (Wallac, Turku, Finland).
Statistical analysis
Data presented are mean ± SEM of triplicate
determinations. Statistical analysis was performed using a
one-way ANOVA. A difference between experimental
groups was considered to be significant when the
probability value was less than 1.0%.
Results
Morphology of cells isolated from fetal femurs
Cell populations isolated from a 12-week-old human fetal
femur (Fig. 1A) and cultured in basal media appeared as
homogenous population of elongated cells with fibroblastic
morphology (Fig. 1C). The homogeneity and cell
morphology did not change when cells were cultured in
an osteogenic medium (data not shown). Histological
analysis of this fetal femur (Fig. 1A) indicates that this
tissue is essentially populated by chondrocytes at different
stages of differentiation with several osteoblastic cell types
forming the perichondrium (Fig. 1B).
Cell proliferation of HFBCs and HMSCs
The requirement of different nutrient-containing culture
media for cell proliferation of HFBCs and HMSCs was
determined in three standard culture media such as DMEM,
DMEM/Ham’s F-12 or αMEM supplemented with 10%
FBS. As shown in Fig. 2A, HFBCs and HMSCs grew more
rapidly in αMEM medium, compared with the other two
media. Cell proliferation was also measured in αMEM
culture medium containing osteogenic factors
(dexamethasone, ascorbic acid and β-glycerophosphate).
In this experimental condition, HMSCs grew faster than
HFBCs (data not shown). To investigate the role of various
growth factors on the proliferation of HFBCs and HMSCs,
mitogenic growth factors were exposed to these cells for
48 h in the standard αMEM medium. Significant effects
on cell number were obtained with FGF-2 and PDGF-BB
for both cell types with a higher response for HMSCs
(100%), compared with HFBCs (50%). FGF1 and PTHrP
also enhanced cell numbers in HMSCs but not in HFBCs.
Wnt3a, an essential factor for commitment of mesenchymal
progenitor cells into osteoprogenitors also significantly
increased cell number in HMSCs with a trend in HFBCs,
whereas BMP-2 slightly enhanced cell number in HFBCs
but not in HMSCs (Fig. 2B).
Osteoblastic phenotype of HFBCs and HMSCs and
regulation by osteogenic factors
To compare the phenotype of HFBCs and HMSCs and
their capacity to differentiate into osteogenic cells in
presence of osteoinductive factors, expression of several
osteogenic and chondrogenic genes were determined after
10 days of culture in either a basic or an osteogenic
medium. Compared with HMSCs cultured in basic
medium, HFBCs expressed higher levels for RUNX2, ALP,
COL1A1 and OCN that are osteoblastic markers (Fig. 3A-
D). In these cells, the presence of osteogenic factors did
not enhance expression of RUNX2, ALP and COL1A1
(Fig. 3A, B and D), and reduced OCN expression (Fig.
Fig. 1. Human fetal bone cell populations. (A) Human fetal femur (12 weeks development). (B) Hemalun-erythrosine
staining showing predominantly cartilaginous tissue. Chondrocytes (vertical arrow) of the diaphysis are surrounded
by the perichondrium containing osteoprogenitor cells (horizontal arrow). (C) Culture of bone cells extracted from
a 12 week-old fetal femur. Cells appeared elongated with a fibroblastic morphology and formed a homogenous
population. Bar = 50 µm.
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3C), whereas in HMSCs, osteogenic factors increased
expression of RUNX2 and COL1A1 (Fig. 3A and D) but
not that of ALP and OCN (Fig. 3B and C). Compared with
human fetal cartilage-derived cells (HFCCs), expression
of the two markers of chondrogenic differentiation SOX9
and COL2A1 was very low or undetectable in both HFBCs
and HMSCs (Fig. 3E and F). Both cell types also expressed
markers of mesenchymal progenitor cell surface, such as
the hyaluronate receptor (CD44) and the thymosin-1 cell
surface antigen (CD90), expression that was not markedly
changed in presence of osteoinductive factors (Fig. 3G
and H).
Effects of BMP-2 on cell proliferation and
differentiation of HFBCs and HMSCs
In basic medium, BMP-2 did not influence cell
proliferation after 48 h incubation in both cell types.
However, proliferation was significantly decreased by
about 20% in HMSCs with an opposite effect in HFBCs
when cultured in the osteogenic medium (Fig. 4A). In
HFBCs cultured in basic medium, BMP-2 had little effects
on markers of early osteoblastic differentiation such as
ALP, RUNX2 and OSX (Fig. 4B, C and D) but markedly
decreased expression of the late marker OCN (Fig. 4E).
When cultured in the osteogenic medium, the increased
Fig. 2. Effects of culture medium and growth factors on proliferation of HFBCs and HMSCs. (A) Replication
curves of human fetal bone cells (HFBCs, empty markers) and mesenchymal stem cells (HMSCs, full markers)
maintained in basal DMEM (?,?), DMEM/F-12 (?,?) or αMEM (?,?) media for 20 days. Cells numbers are
expressed relative to cell counts at day 0. (B) Effects of various growth factors on HFBCs proliferation (white bar)
and HMSCs (black bar) in αMEM culture medium (concentrations and incubation time are mentioned in Materials
and Methods). Cell numbers are expressed as ratios with their respective controls (incubation with vehicles). Data are
presented as mean ± SEM from triplicate determinations of a representative experiment. **p<0.001, significant from
untreated HFBCs; °p<0.01, °°p<0.001, significant from untreated HMSCs.
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Fig. 3. Quantitative gene expression levels in response to osteogenic factors in HFBCs and HMSCs. Total
RNA was extracted in confluent cells and quantitative PCR analysis for RUNX2 (A), ALP (B), OCN (C), COL1A1
(D), SOX9 (E), COL2A1 (F), CD44 (G) and CD90 (H) gene expression was performed. HFBCs and HMSCs were
maintained in basal αMEM medium (white bar) or in osteoinductive αMEM medium (black bar) for 10 days.
Human fetal cells isolated from mixed cartilage (hFCCs), and cultured in chondrogenic conditions (DMEM
supplemented with 2 mM L-glutamine, 1x Insulin-Transferrin-Selenium (ITS), 10 mM sodium pyruvate, 40 µg/ml
L-proline, 50 µg/ml ascorbic acid and 10 ng/ml TGF-β3) for 10 days were used as reference for SOX9 and COL2A1
mRNA. MG-63 cell line, maintained in αMEM base medium without any osteogenic factors, served as a control
source for osteoblastic markers. mRNA quantification is presented as relative expression of 2-∆∆CT values. Red
figures indicate significant statistical difference between the 2 tested media and green figures indicate significant
statistical difference between HFBC and HMSC.
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cell number in HFBCs was associated with a decrease in
all markers of osteoblastic differentiation (Fig 4B-E).
Associated with the decreased cell number induced by
BMP-2 in HMSCs cultured in the osteogenic medium, cell
differentiation assessed by measurements of ALP and OCN
expression was significantly increased (Fig. 4B and E).
Surprisingly, expression of RUNX2 was upregulated by
osteogenic factors and not by BMP-2 (Fig. 4C) suggesting
the implication of a RUNX-2-independent mechanism
(Matsubara et al., 2008), whereas BMP-2-induced
enhancement of OSX expression was independent of the
presence of osteogenic factors (Fig. 4D). These
observations strongly suggested that BMP-2 differentially
regulates HFBCs and HMSCs.
Molecular mechanism by which BMP-2 enhances cell
proliferation in HFBCs
In order to investigate the molecular mechanism by which
BMP-2 enhances the proliferation of HFBCs, we first
determined the time required for an optimal proliferative
Fig.  4. Effects of BMP-2 on HFBCs and HMSCs. (A) BMP-2 increased HFBCs proliferation. Number of HFBCs
(white bars) and HMSCs (black bars) was measured 48 hours after incubation with a single dose of BMP-2 (50 ng/
ml). (B) Regulation of alkaline phosphatase (ALP) activity by BMP-2 in basal medium (BM) and in osteogenic
medium (OM) in HFBCs and HMSCs after 10 days of treatment. Culture medium supplemented with BMP-2 was
renewed every 3 days. (C-E) Effect of BMP-2 on gene expression. RUNX2 (C), OSX (D) and OCN (E) mRNA
levels were quantified by real-time PCR 10 days post-treatment with BMP-2 and/or osteoinducive supplements.
Data presented are mean of three independent cultures ± SEM. *p<0.01 versus untreated (BM) HFBCs; °p<0.01
and versus untreated (BM) HMSCs.
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response (Fig. 5A). After 4 days incubation, cell number
was increased by 25-30% and a maximal effect was
observed after 8 days exposure to 50 ng/ml BMP-2 (55-
60%). For analysis of signaling pathways involved in this
response, several selective inhibitors were used and data
are presented in Fig. 5B. As expected, the specific BMP-2
antagonist completely inhibited this effect with little effect
on basal proliferation. Inhibition of the ERK pathway
(U0126) slightly but significantly reduced the BMP-2-
induced cell proliferation whereas the p38 inhibitor
SB202190 enhanced both the basal proliferation and the
BMP-2 proliferation (Fig. 5B). Major inhibitory effects
were observed with inhibitors of JNK (SP600125), Src
kinases (CGP77675) and PKC (GO6983). These inhibitors
Fig. 5. Time effect of BMP-2 on HFBCs proliferation and analysis of signaling pathways involved in this
response. (A) Cells cultured in the osteogenic medium were exposed for various incubation times to BMP-2 (D =
days) and cell number was assessed by cell counts. (B) Subconfluent cells cultured in the osteogenic medium were
preincubated with either Noggin or various selective signaling pathways inhibitors (U0126 = MEK Inhib; SB202190
= p38 Inhib; SP600125 = JNK Inhib; CGP77675 = Src Inhib; GO6983 = PKC Inhib) and then treated with 50 ng/ml
of BMP-2 for 8 days. Cell number was then determined by cell counting. Data presented are mean ± SEM of
triplicate determinations from a representative experiment. *p<0.01 compared with the respective control; °p<0.01
compared with either vehicle or BMP-2 untreated cells.
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not only diminished the BMP-2 proliferative effect but
also markedly reduced basal cell proliferation suggesting
an important role of these pathways in controlling the
proliferation of HFBCs.
In vitro mineralization in HFBCs and HMSCs
Semi-quantitative analysis of extracellular matrix
calcification by Alizarin red staining in both cell types are
presented in Fig. 6. After 21 days of culture in an osteogenic
medium, the amount of mineral accumulated in the
extracellular matrix of HFBCs was higher compared with
that of HMSCs. In both cell type, however, there was no
stimulatory effect of 50 ng/ml BMP-2 on this parameter
(Fig. 6).
Discussion
Data presented in this study indicate that cells isolated from
12-14 week old fetal femurs present characteristics of
advanced osteoprogenitors compared with human
mesenchymal stem cells isolated from bone marrow. They
show a similar growth rate in αMEM medium with similar
mitogenic responses to growth factors but a different
regulation of their proliferation and differentiation by
BMP-2. When cultured in an osteogenic medium, they
synthesize a higher amount of mineralized matrix
compared with HMSCs in association with higher
expression of osteoblastic markers. In the isolation
procedure, small pieces of the entire femur were deposited
in a Petri dish and cells that colonized the surface of the
dish were harvested. Even though at that stage of 12-14
weeks development the femur mainly contained
chondrocytes and periosteal cell layers (Fig. 1), the isolated
population was homogenous with cells having a spindle-
like shape, and no expression of chondrocytes markers. It
is likely that cells isolated by this method have high
migration and proliferation capacities which are
characteristics of mesenchymal progenitors (Wu et al.,
2007).
Thus, it was not surprising that these cells had similar
growth and mitogenic factors responses compared with
HMSCs. A first biological characterization of HFBCs has
already been reported indicating that these cells have a
higher capacity to proliferate compared with human
osteoblasts and a higher capacity to differentiate in vitro
into bone cells compared with mesenchymal cells
(Montjovent et al., 2004). In addition, promising results
have been presented concerning the use of these cells
associated with ceramic reinforced poly(L-lactic acid)
structures for bone regeneration (Montjovent et al., 2008).
From these observations suggesting a high potential of
these cells in tissue engineering, we further investigated
the biological characteristics of these cells and determined
what are the regulating factors influencing their expansion
and differentiation in vitro compared with human
mesenchymal cells. A first important new observation was
the much higher proliferation of HFBCs in αMEM
compared with DMEM or DMEM/Hams-F12, an effect
also observed with HMSCs (Fig. 2A). This result could
be explained by the different composition of nutrients, for
which those contained in αMEM are more appropriate for
Fig. 6. Osteogenic differentiation of HFBCs and HMSCs. Extracellular matrix mineralization was induced in
confluent monolayers of HFBCs and HMSCs cultured either in basal (BM) or osteogenic (OM) medium with or
without BMP-2 (50 ng/ml) for 21 days. Matrix mineralization was evaluated by Alizarin Red (OD 595) staining.
Data presented are mean ± SEM from triplicate determinations of a representative experiment.
55 www.ecmjournal.org
N Krattinger et al.                                                                         Characterization and regulation of human fetal bone cells
the development and the physiology of fibroblastic-cell
types. To date, only one other study has reported on the
effect of several growth media on proliferation of fetal
femur-derived cells (Mirmalek-Sani et al., 2009).
However, these cells were taken at 8 weeks of development
(only one in fetal development stage), which thus
represents stem cells and not fetal (> 9 weeks) by definition.
In αMEM medium, we observed that both HFBCs and
HMSCs had a similar growth rate and similar responses to
PDGF-BB, FGF-2 and to a smaller extent to Wnt3a and
IGF-1 (Fig. 2B). They responded, however, differently to
FGF-1, PTHrP and BMP-2. The two former growth factors
stimulated HMSCs whereas BMP-2 slightly enhanced the
proliferation of HFBCs but not that of HMSCs (Fig. 2B).
These data are consistent with previous studies reporting
that PDGF-BB induced replication and inhibited bone
matrix formation in the intermediate osteoprogenitor zone
of fetal rat calvariae (Hock and Canalis, 1994), and that
FGF-2 maintained undifferentiated progenitor cells in an
immature state, allowing in vitro expansion (Martin et al.,
1997; Tsutsumi et al., 2001). PDGF-BB and FGF-2 may
thus promote the creation of a large pool of fetal
osteoblasts, inducing them to differentiate into mature
osteoblasts. Further characterization of HFBCs cultured
in either a normal αMEM medium or an osteogenic
medium has been obtained with analysis of the expression
of the earliest markers required for the process of
osteoblastogenesis compared with HMSCs. In a normal
αMEM medium when cells rapidly expanded in culture,
HFBCs expressed higher levels of bone markers such as
RUNX2, ALP, OCN and COL1A1 compared with HMSCs
(Fig. 3A-D) suggesting that HFBCs are more advanced in
their osteogenic program compared with HMSCs.
Moreover, both cell types responded differently to
osteogenic factors. Whereas HFBCs maintained their
differentiation characteristics in presence of
dexamethasone and other osteoinductive factors, HMSCs
enhanced some of the bone markers such as RUNX2 and
COL1A1 in accordance with previous data (Frank et al.,
2002). However, the presence of osteogenic factors are
necessary for the formation of a significant amount of
mineralized tissue in both cell types (Fig. 6), suggesting
the crucial role of these factors in the maturation of
osteoprogenitor cells to functional osteoblasts, as widely
mentioned in the literature (Jaiswal et al., 1997;
Montjovent et al., 2004; Montjovent et al., 2005). Finally,
HFBCs and HMSCs did not express cartilage markers such
as SOX9 and COL2A1 (Fig. 3 E and F). However, CD44
and CD90, two markers of mesenchymal progenitor
surface, were present.
As mentioned above, we found that BMP-2 slightly
enhanced the proliferation of HFBCs but not that of
HMSCs (Fig. 2B). Increased proliferation of some
mesenchymal stem cells by BMP-2 has already been
reported (Liu et al., 2009; Shoji et al., 2010). Since BMP-
2 is a potential inducer of bone regeneration (Lecanda et
al., 1997), additional experiments were performed to
clarify the effects of BMP-2 on HFBCs proliferation and
differentiation. Surprisingly, BMP-2 had opposite effects
on HFBCs proliferation and differentiation compared with
HMSCs (Fig. 4). The enhanced proliferation in HFBCs
was associated with inhibition of bone marker expression,
an effect that was more pronounced in presence of
osteogenic factors (Fig. 4). This response is typical of
mesenchymal cells already committed to a cell lineage. In
HMSCs that are less differentiated cells compared with
HFBCs, they probably did not differentiate into osteogenic
cells when cultured in the basal culture medium, thus
explaining the observed decreased ALP activity. When
cultured in the osteogenic medium, they started to
differentiate into osteogenic cells thus explaining the
increased ALP activity in response to BMP-2 (Fig. 4).
Surprisingly, these differential effects of BMP-2 between
HFBCs and HMSCs did not influence the matrix
mineralization capacity of each cell type (Fig. 6), perhaps
because the 50 ng/ml dose was not sufficient compared
with other differentiating factors to promote the synthesis
of a mineralized matrix.
Analysis of signaling pathways involved in BMP-2–
induced HFBCs proliferation suggest that Src kinase(s),
PKC and JNK are major transduction pathways involved
in controlling basal and BMP-2 induced cell proliferation
in these cells. The cellular and molecular mechanisms
responsible for inducing either a proliferative or a
differentiating response in osteoprogenitor cells remains
unclear but may be explained by expression of different
receptors of the transforming growth factor-β family. BMP
initiates signaling upon ligand binding to the high affinity
type I BMP signaling receptors, activin-like receptor
kinase-1 (ALK-1), ALK-2, ALK-3, or ALK-6 (Miyazono
et al., 2001). The level of expression of each receptor and
of various partner signaling proteins determines the variety
of biological activities induced by BMP proteins. Further
investigation will be required to explain the molecular
mechanism by which BMP-2 induces HFBCs proliferation.
One of the major advantages of human fetal bone cells
(HFBCs) compared to adult MSC is that only one organ
donation is enough to treat hundreds of thousands of
patients (Applegate et al., 2009). It has been previously
shown with human fetal skin cells that variability between
cell lines is minimal compared to young and adult cell
lines. Cell banking techniques are thus possible to create
the one stock of cells for clinical use following extensive
testing for safety. There is then no need to evaluate the
variability of HFBCs behavior between samples as
ultimately, in the clinical application, only one donor source
will be used. However, the characterization for this sample
will be extensive (Quintin et al., 2007).
In conclusion, HFBCs have a high capacity to migrate
and proliferate in αMEM medium and are more advanced
in their osteogenic program compared with HMSCs from
the bone marrow strongly suggesting that these cells are
osteoprogenitors derived from the periosteum. Their
proliferation can be further increased in presence of PDGF-
BB and FGF-2 as well as by BMP-2 by a cellular
mechanism that remains to be investigated. Given their
high capacity to proliferate and their expression of
osteogenic characteristics in the absence of differentiating
factors, these cells are of potential interest for therapeutic
use in bone tissue engineering.
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Discussion with Reviewers
Reviewer I: Please explain the potential pros and cons of
the human fetal bone cells compared to marrow-derived
human mesenchymal stem cells.
Authors: One of the major advantages of human fetal bone
cells (HFBCs) compared to adult mesenchymal stem cells
(MSCs) is that only one organ donation is enough to treat
hundreds of thousands of patients. It has been previously
shown with human fetal skin cells that variability between
cell lines is minimal compared to young and adult cell
lines and thus “pooling” of cell lines would not be
necessary and even undesired. Cell banking techniques
are thus possible to create the one stock of cells for clinical
use following extensive testing for safety which is required
for the development of a therapeutic product. There is then
no need to evaluate the variability of HFBCs behavior
between samples as ultimately, in the clinical application,
only one donor source will be used. However, the
characterization for this sample will be extensive.
Reviewer I: In general, proliferation of a cell precedes its
differentiation. How do you explain the opposite behavior
of HFBC and HMSCs upon BMP2 stimulations?
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Authors: It is correct that in general, proliferation of a
cell precedes its differentiation. However, at early stages
of mesenchymal cell differentiation, cells just may slow
down their differentiation and continue their proliferation.
The different behavior of HFBCs and HMSCs to BMP2
stimulation is probably related to their different stage of
differentiation. HFBCs are at an early stage of osteoblastic
differentiation and at that stage, BMP2 induces an
increased proliferation associated with a lower ALP
activity. In HMSCs that are undifferentiated mesenchymal
cells, BMP2 induced their differentiation and this effect is
associated with a lower proliferation.
Reviewer I: Human fetal bone cells may be quite well
tolerated in their fetal state, perhaps due to low level
expression of major histocompatibility complex “tissue
antigens”. But what about the differentiated cells: do they
not start to express MHC molecules, which can evoke
immunological rejection and may necessitate
immunosuppression of the recipient to improve graft
survival?
Authors: Effectively, we showed that human fetal bone
cell have a reduced expression of HLA-1 compared to adult
osteoblasts (Montjovent et al., 2009). When fetal bone cells
stimulated toward osteoblast differentiation, we did not
see an increased expression of HLA-1. We cannot exclude
though that the expression of HLA-1 increased when the
cells are more differentiated. However, this should not
represent a problem as the target of fetal cell therapy is to
use them as initial growth factor reservoir to induce bone
formation and not to produce bone extracellular matrix.
The delayed immunological rejection would then not affect
the initiation of bone healing through the release of growth
factors by the fetal cells. Additionally, clinical trials with
fetal skin cells in humans did not show any sign of immune
rejection even following multiple treatments.
Reviewer II:  How do the authors explain the effect of
BMP-2 in HMSCs, regarding ALP activity (in base
medium it decreases but in osteogenic medium it increases
sharply)?
Authors: In basal medium, HMSCs have the potential to
differentiate into various cell types. Therefore, the decrease
of ALP activity suggests that when cultured in this medium,
HMSCs were not differentiating into osteoblastic or
chondrogenic cells and thus explaining the decreased ALP.
When cultured in the osteogenic medium, they
differentiated into osteogenic cells therefore explaining the
increased ALP activity.
Reviewer II:- Based on Fig. 6B, although the
mineralization was higher in HFBCs, in absolute terms,
when compared with HMSCs it is not like that. In fact, the
mineralization in base medium is about 50% lower in
HMSCs, that is, the increase caused by osteogenic medium
in that condition was higher than in HFBCs cultures. Please
comment.
Authors: It is correct that the increase in mineralization
between basal and osteogenic medium was higher in
HMSCs compared with HFBCs. This is due to the more
advanced phenotype of HFBCs compared with HMSCs
with higher basal mineralization activity in basal medium
of HFBCs. Since both cell types are derived from the same
progenitor cells, they reach similar osteoblastic activity
when cultured in optimal osteogenic conditions.
Reviewer II:  The authors say that HFBCs express higher
levels of osteoblastic markers than HMSCs, which lines
with a higher commitment to osteoprogenitor
differentiation. However, the growth rates of HFBCs and
HMSCs are similar. Please comment on this situation,
because usually, proliferation decreases with the degree
of differentiation.
Authors: In general, an increase in osteoblastic cell
proliferation is associated with a decrease in cell
differentiation. This association, however, is not always
observed in mesenchymal stem cells which often have the
potency to commit themselves to a cell phenotype while
keeping a high capacity to proliferate. In HFBCs, BMP2
effectively induced a proliferative response and during cell
replication, the bone differentiation parameters were
decreased. An opposite response was observed in HMSCs
which are cells less differentiated compared with HFBCs.
This type of response is also observed in the ST2
mesenchymal cell line in response to Wnt3a and BMP-2
(personal observations). In these cells, Wnt3a and BMP-2
induce both an increase in proliferation and a marked
increase in alkaline phosphatase activity. Thus, whereas it
is generally accepted that proliferating cells decreased their
differentiating potential, undifferentiated mesenchymal
cells have the capacity to differentiate while still
proliferating.
Reviewer II: The presence of osteogenic medium seems
not to affect ALP, Runx2 and Col1A1 expression in
HFBCs, and OCN expression is even lowered in those
conditions. However, when we observe Fig. 6, there is a
clear stimulation of osteoblastic differentiation induced by
osteogenic medium. How is this possible?
Authors: Analysis of osteoblastic marker expression has
been performed at day 10 in culture probably representing
an early stage of differentiation. Marker expression
probably increases later during the differentiation process.
The time course of this expression is likely to be different
between the two cell types and difficult to assess since it
probably varies between experiments. Matrix
mineralization is an appropriate measure of cell
differentiation that integrates all processes leading to a
calcified matrix.
Additional Reference
Montjovent MO, Bocelli-Tyndall C, Scaletta C,
Scherberich A, Martin I, Laurent-Applegate L., Pioletti
DP (2009) In vitro characterization of immune-related
properties of human fetal bone cells for potential tissue
engineering applications. Tissue Eng 15: 1523-1532.
